Kazia Expands Paxalisib Trial to HR+/HER2- Breast Cancer on Strong Preclinical Data
KZIA has more than doubled off its 52-week low of $4.86.
Summary
Kazia is expanding its ongoing TNBC trial into HR+/HER2- breast cancer, a much larger patient population, after preclinical data showed paxalisib combined with standard-of-care produced statistically significant antitumor activity and resensitized CDK4/6 inhibitor-resistant tumors. The three-arm expansion will test paxalisib plus fulvestrant, with palbociclib, versus fulvestrant alone, with first patient expected by year-end 2026 and full enrollment by end of 2027. This follows the recent $40M financing and the 100% clinical benefit rate reported in TNBC, giving the company capital to fund the program through completion. The move addresses a major unmet need in HR+/HER2- breast cancer, which accounts for 60-70% of all breast cancer diagnoses, and the company has filed a provisional patent on a novel PI3K/mTOR biomarker to enrich for high-risk patients. Full data readout is anticipated in 2028.
At the time of this announcement, KZIA was trading at $14.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.3M. The 52-week trading range was $4.86 to $17.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.